Observations placeholder
Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study.
Identifier
020261
Type of Spiritual Experience
Background
The trials required that suppeent was used to ensure the results could be monitored, but arginine is btainabe from many foods. We have thus provided a link t Arginine, which itslef will give you the link to the foods it is in.
A description of the experience
Eur Respir J. 2005 Jan;25(1):62-8.
Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study.
Grasemann H1, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F.
- 1Children's Hospital, University of Essen, Hufeland Str. 55, D-45122 Essen, Germany. hartmutg@hotmail.com
Abstract
Exhaled nitric oxide (eNO) is decreased in cystic fibrosis (CF). The effect of oral L-arginine, the precursor of enzymatic nitric oxide (NO) formation, on airway NO in patients with CF was studied. In a pilot study, oral L-arginine was given in a single dose of 200 mg x kg(-1) body weight to eight healthy controls and eight CF patients. Subsequently, the same L-arginine dose was given to 10 patients with CF (five females) t.i.d. for 6 weeks in a randomised double-blind placebo-controlled crossover study. A single dose of oral L-arginine resulted in a 5.5-fold increase of L-arginine in plasma and a 1.3-fold increase of L-arginine in sputum after 2 h. Maximum eNO, within 3 h of L-arginine intake, increased significantly in both CF patients (5.4+/-2.1 ppb versus 8.3+/-3.5 ppb) and controls (18.0+/-8.1 ppb versus 26.4+/-12.3 ppb). Supplementation of L-arginine for 6 weeks resulted in a sustained increase in eNO compared to placebo (9.7+/-5.7 ppb versus 6.3+/-3.1 ppb). An effect of L-arginine supplementation on forced expiratory volume in one second was not observed. These data indicate that airway nitric oxide formation in cystic fibrosis patients can be augmented with oral L-arginine supplementation.
PMID: 15640324